The FDA has given marketing approval to the drug Cesamet, which contains a synthetic cannabinoid. Cannabinoids are the active ingredients in marijuana. Cesamet treats chemotherapy-related nausea and ...
COSTA MESA, Calif.--(BUSINESS WIRE)--May 16, 2006--Valeant Pharmaceuticals International (NYSE:VRX) today announced that the U.S. Food and Drug Administration (FDA) has given marketing approval for ...
COSTA MESA, Calif.--(BUSINESS WIRE)--Aug. 17, 2006--Valeant Pharmaceuticals International (NYSE:VRX) today announced the availability of Cesamet (CII) (nabilone) oral capsules in U.S. pharmacies ...
1. “In scientific studies, patients who took Cesamet had 3 types of benefits. They vomited less often, felt less nauseous, and were able to eat more than patients who did not take Cesamet. Patients ...
LOS ANGELES (Reuters) - A synthetic version of the active ingredient in marijuana, a legal treatment for nausea in cancer patients undergoing chemotherapy, also helps symptoms like pain, anxiety and ...
The mislabelling of a bottle of drugs has prompted Health Canada to issue an advisory warning patients to check their prescriptions of Trazorel and Cesamet. The agency said Tuesday that Montreal-based ...
Valeant Pharmaceuticals has won marketing approval in the USA for Cesamet, a drug to treat nausea and vomiting associated with cancer chemotherapy, 17 years after it was taken off the market. Valeant ...
Valeant Pharmaceuticals International said Friday that the Food and Drug Administration quashed its request for a labeling change for Cesamet, delaying the launch of the anti-vomiting drug. Costa Mesa ...
Valeant Pharmaceuticals International ended 2005 on a sour note after it received a non-approvable letter from the US Food and Drug Administration for Cesamet (nabilone), a cannabinoid drug for ...
Review the side-effects of Nabilone as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
WOODCLIFF LAKE, N.J., Nov. 2 (UPI) -- U.S firm Par said Thursday it will no longer promote Valeant's antiemetic drug Cesamet starting November 15. Par said Valeant exercise its right to terminate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results